Tech Company Financing Transactions
Atopix Therapeutics Funding Round
Atopix Therapeutics, operating out of Abingdon Oxon, secured investment capital from GlaxoSmithKline and SR One Capital Management.
Transaction Overview
Company Name
Announced On
10/8/2014
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
SR One Capital Management (Deborah Harland)
Proceeds Purpose
The additional funds provided by SR One will be used to complete the evaluation of Atopix's lead CRTH2 antagonist OC459 in atopic dermatitis and to assess the safety and pharmacokinetic profile of its highly potent back-up molecule ATX2417 in Phase I studies.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
99 Park Dr. Milton Park
Abingdon Oxon, OX14 4RY
UK
Abingdon Oxon, OX14 4RY
UK
Phone
Website
Email Address
Overview
Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Timothy Edwards
Chief Medical Officer
Andrew Zambanini
Chief Scientific Officer
Mick Hunter
Browse more venture capital transactions:
Prev: 10/8/2014: Atlas Wearables venture capital transaction
Next: 10/8/2014: Comply365 venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs